RalBP1 Is Necessary for Metastasis of Human Cancer Cell Lines  by Wu, Zhong et al.
RalBP1 Is Necessary for
Metastasis of Human
Cancer Cell Lines1
Zhong Wu*, Charles Owens*, Nidhi Chandra*,
KayPopovic†,MarkConaway‡andDanTheodorescu*,§
*Department of Molecular Physiology and Biological
Physics, University of Virginia, Charlottesville, VA, USA;
†Department of Radiology, University of Virginia,
Charlottesville, VA, USA; ‡Department of Public
Health Sciences (Biostatistics), University of Virginia,
Charlottesville, VA, USA; §Paul Mellon Prostate Cancer
Institute, University of Virginia, Charlottesville, VA, USA
Abstract
RalA expression in human prostate cancer is associated with cell migration and is necessary for bone metastasis.
However, the downstream effectors of RalA that mediate these functions remain unclear. Here we examined cell
migration after small interfering RNA–mediated depletion of Ral effectors Ral binding protein 1 (RalBP1/RLIP), exo-
cyst complex component 2 (Sec5), and phospholipase D1 (PLD1) and found that RalBP1 and RalA depletion inhibited
cell migration to a similar extent. Stable lentivirus short hairpin interfering RNA–mediated depletion of RalA and
RalBP1 in PC3 human prostate cancer cells inhibited bone metastasis after intracardiac inoculation. Depletion of
RalBP1 diminished orthotopic tumor growth of PC3 cells and inhibited spontaneous metastasis from this site. Inter-
estingly, the expression of wild-type or RalA mutants deficient in RalBP1 binding was effective at rescuing the re-
ducedmetastatic capacity of RalA-depleted PC3 cells, suggesting that RalA depletion does not reduce this solely by
diminished interaction with RalBP1. To determine whether the role of RalBP1 in metastasis is relevant beyond pros-
tate cancer, we studied the requirement of RalBP1 expression in an experimental metastasis model of human blad-
der cancer, a tumor type with high RalBP1 expression. Depletion of RalBP1 in UMUC3 cells resulted in decreased
lung colonization while having a minimal effect on subcutaneous tumor growth. Our studies are the first to suggest
that the expression of RalBP1 is necessary for human cancer cell metastasis. Furthermore, we show that the require-
ment for RalA expression for manifestation of this phenotype is not entirely dependent on a RalA-RalBP1 interaction.
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Introduction
RalA and RalB GTPases are monomeric G proteins of the Ras super-
family with 82% amino acid identity [1]. Ral proteins were initially
implicated in Ras-mediated transformation of human cells [2] as well
as in maintenance of the Ras-driven malignant phenotype [3]. Recent
evidence also indicates their essential role in cancer progression and
metastasis. Both RalA and RalB have been shown to be involved in
pancreatic cancer cell metastasis [4]. In contrast, RalA but not RalB
was necessary for prostate cancer PC3 cells to metastasize to bone after
stable expression of RNA interference for Ral paralogs [5]. We recently
observed that RalA expression in bladder tumors is associated with
higher stage [6]. Experimentally, RalA and RalB depletion after tran-
sient small interfering RNA (siRNA)–mediated knockdown was asso-
ciated with decreased cell growth and migration in both bladder and
prostate cancer cells [7]. However, the downstream signaling pathways
that mediate Ral function in migration and metastasis are unclear.
On activation, Ral paralogs bind to several effectors includ-
ing RalBP1 (RLIP), exocyst components (Sec5 and Exo84), filamin,
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phospholipase D1 (PLD1), and ZONAB, and this results in diverse
Ral-associated functions [1]. RalBP1 is the best-characterized Ral ef-
fector, and previous results suggested its association with Ral-mediated
tumorigenesis [3]. Furthermore, expression of RalBP1 is increased in
human bladder cancer tissues compared with normal tissues, and its
level was correlated with Ral expression [6]. Depletion of RalBP1 by
antisense or inhibition of its function by antibody decreased subcutane-
ous xenograft tumor growth in a number of cancer cell lines [8,9]. Sim-
ilar to RalBP1, the exocyst complex component Sec5 has been shown
to be involved in Ral-mediated transformation [3]. PLD1 was also as-
sociated with cells transformation by oncogenes including Ras [10,11].
Although these Ral effectors have been implicated in transforma-
tion, their functional role in Ral-mediated cancer progression has
not been clearly defined. Here, we begin by examining the function
of Ral effectors on cell migration and find that RalBP1 depletion
inhibited cell migration to a similar extent as RalA depletion did in
human prostate cancer cells. Further examination of the consequences
of stable depletion of RalBP1 in prostate and bladder cancer cells
points to an important role for RalBP1 in cancer metastasis.
Materials and Methods
Cell Culture and Counting
Human bladder cancer UMUC3 and prostate cancer PC-3 cell lines
were obtained from American Type Culture Collection (Rockville,
MD), and cultures were as described. For counting assays, cells were
plated at a concentration of 1000 cells per well in 200 μl in 96-well
tissue culture plates (Corning Incorporated, Corning, NY). Replicate
plates were plated for each indicated time point. At each time point,
10 μl of Alamar blue was added to each well, and fluorescence was
measured 4 hours later on a microplate reader (BioTek, Winooski,
VT) with excitation at 520 nm and emission at 570 nm.
Short Hairpin Interfering RNA and siRNA Reagents
and Transfection
The NH2-terminally Flag-tagged RalA expression pFlag-CMV-4
vector was described previously [7]. The RalA sequence 5′-CGAT-
GAGTTTGTGGAGGACT-3′ was targeted by short hairpin interfer-
ing RNA (shRNA). Lentiviral shRNA expression vectors targeting
RalA, RalB, and RalBP1 were purchased from Sigma (St Louis,





TAAGCAAATTCTCTGGTTTTTG-3′), and RalBP1-3 shRNA
(5′-CCGGGCACAAGAGATAGCCAGTCTTCTCGAGAA-
GACTGGCTATCTCTTGTGCTTTTTG -3′) were encoded in a
lentiviral expression vector, PLKO, which carries a puromycin selec-
tion marker. The same lentiviral vector containing a nontarget shRNA
sequence that does not target any human gene was used as control. The
SFGnesTGL vector expressing a thymidine kinase/green fluorescent
protein/luciferase (TGL) fusion protein was described [12]. All
plasmid DNA used for transfection was prepared by the “EndoFree
Plasmid Maxi kit” from Qiagen (Valencia, CA).
siRNA duplexes were purchased fromDharmacon (Lafayette, CO).
RalA targeting siRNA was described previously [7]. RalBP1-targeting
siRNA duplexes were a mixture of two individual duplex with the fol-
lowing targeting sequence: 5′-GAACGAAGAGCUGGAAAUAUU-3′
and 5′-GAAGGCAUCUACAGAGUAUUU-3′. siRNA duplexes tar-
geting Sec5 and PLD1 were smart pools, and the siRNA duplex target-
ing luciferase (GL2), 5′-CGTACGCGGAATACTTCGA-3′, was used
as control siRNA. Transfection of cells with siRNA duplexes (100 nM)
was done using OligofectAMINE (Invitrogen, Carlsbad, CA).
Establishment of Luciferase-Expressing Stable Knockdown or
Overexpressing Cells
Parental UMUC3 and PC3 cells were stably transfected with line-
arized SFGnesTGL vector, and luciferase-expressing cells were selected
by fluorescence-activated cell sorting of green fluorescent protein. To
generate stable RalA and RalBP1 knockdown cells, RalA and RalBP1
shRNA constructs were cotransfected with lentiviral package plasmids
CMVΔR8.2 and pMD.G into 293T cells. Viral particles harvested
48 hours after transfection were used to infect luciferase-expressing
UMUC3 and PC3 cells. Positive cells were selected with 2 μg/ml pu-
romycin, and the knockdown of Ral and RalBP1 was confirmed by
Western blots. To make stable RalA and RalBP1 expression PC3 cells,
flag-tagged wild-type RalA, D49Nmutant RalA, RalBP1, and flag vec-
tor control were stably transfected into luciferase-expressing PC3 cells.
These constructs had silent mismatch mutations that allowed them
be expressed despite the presence of shRNA. After 1 mg/ml G418
selection, pools of positive cells were confirmed with Western blots.
Cell Chemotaxis and Plating Efficiency Assays
PC3 cells were transfected with siRNA oligo duplexes to transiently
knockdown of RalA, RalBP1, Sec5, and PLD1. Cells were harvested
72 hours after transfection and counted in a hemacytometer and were
resuspended in serum-free Dulbecco modified Eagle medium
(DMEM)/F12 medium. Cells (20,000) were added in triplicate to
the upper chamber of transwell filters (8.0 μmpores; BectonDickinson,
Franklin Lakes, NJ) in a 24-well tissue culture plate. The lower
chambers contained 0.65 ml of DMEM/F12 with 2% FBS. For plat-
ing control, same number of cells was added in duplicate in wells of
96-well plate (roughly the same growth area compared with the upper
chamber of transwell) containing 50 μl of DMEM/F12 medium with
2% FBS. After 20 hours of plating, cells remaining on the upper sur-
face of the filters were removed with cotton swabs, and cells on the
lower surface were fixed with 100% methanol, stained with crystal
violet, and counted with the aid of a grid coverslip (Bellco Biotechnol-
ogy, Vineland, NJ). Cell numbers in plating control wells of 96-well
plates were determined with CyQuant (Invitrogen) according to man-
ufacturer’s instructions.
Real-time Reverse Transcription–Polymerase Chain
Reaction Analysis
Real-time reverse transcription–polymerase chain reaction (RT-PCR)
was carried out on iCycler Optical Module (Bio-Rad, Hercules, CA)
with IQ SYBR Green (Bio-Rad) fluorescent dye included in the PCR
to determine the amount of messenger RNA (mRNA) level for RalA,
RalBP1, Sec5, and PLD1. Primers used for RalA were forward
5′-CAGACAGCTATCGGAAGAAG-3′ and reverse 5′-AGAAAAC-
ACAGAGGAACCCC-3′. Primers for RalBP1 were forward 5′-ACC-
GGGAGGAGTCTACAAAC-3′ and reverse 5′-CCTCTTCAAATCT-
GGGCATA-3′. Primers for Sec5 were forward 5′-ATGTCCTC-
ACTTGGGTCAT-3′ and reverse 5′-GCTCGCTCACGCCATC-
CAG-3′. Primers for PLD1 were forward 5′-CAGAGCTTGGTAAT-
CAGTGG-3′ and reverse 5′-GCGGTCATTTATGTTGGCAG-3′.
Real-time RT-PCR for glucuronidase β (Gusb) was used as an internal
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control, and primers were forward 5′-CCGACTTCTCTGACAACC-
GACG-3′ and reverse 5′-AGCCGACAAAATGCCGCAGACG-3′.
Expression levels of RalA, RalBP1, Sec5, and PLD1 were normalized
to the expression of glucuronidase β in each sample by calculating the
ratio of individual gene expression to Gusb expression.
Western Blot Analysis
Protein extracts were prepared from stable Ral- and RalBP1-depleted
UMUC3 and PC3 cells. Western blots were carried out as described
[13] using commercial chemiluminescence reagents (SuperSignalWest
Femto; Pierce, Rockford, IL) and α-imaging (Alpha Innotech, San
Leandro, CA). The anti-RalA monoclonal antibody was purchased
from BD Transduction Laboratory (Franklin Lakes, NJ) and used at
1:1000 dilution. The polyclonal anti-RalBP1 (Abnova, Walnut, CA)
antibody was used at 1:2000 dilution. Themonoclonal anti–α-tubulin
antibody was purchased from Oncogene (San Diego, CA) and was di-
luted at 1:2000. The HRP-conjugated antimouse and antirabbit sec-
ondary antibodies were both from Pierce and were used at 1:2500
Figure 1. In vitro and in vivo PC3 characterization after depletion of Ral and its effectors. (A) MRNA expression levels of Ral and effectors
72 hours after transient siRNA transfection of PC3 cells with siRNA targeting RalA, RalBP1, Sec5, and PLD1. Cells were lysed for RNA
extraction, and expression levels were quantitated by RT-PCR with primers specific for RalA, RalBP1, Sec5, and PLD1. Expression levels
were normalized with glucuronidase-β (Gusb) by calculating the ratio between individual gene expression and Gusb expression as
described in Materials and Methods. (B) Duplicate plate transfected with siRNA was harvested at 72 hours after transfection, and
2 × 104 cells were plated in the upper compartment of a Boyden chamber in serum-free medium, whereas 2% FBS-containing medium
was added into the bottom compartment. Cells were allowed tomigrate for 20 hours. Statistical significance compared with siGL2 control
siRNAwas indicated by *P< .05 and **P< .01. (C) Western blots demonstrating decreased RalA and RalB protein levels in PC3 cells after
infection of lentiviral-based RalA and RalB targeting shRNA constructs shRalA-5 and shRalB-4. (D) Subcutaneous tumor growth of non-
target shRNA PC3 tumors and RalA as well as RalB knockdown tumors. PC3 cells in serum-free RPMI medium were mixed with Matrigel
and were subcutaneously injected into the mouse flank region in 10 mice per group with two sites per mouse. Tumor volume was mea-
sured every week with calipers. *P < .05 compared with sh-nontarget control at 5 weeks. (E) Xenogen evaluation of metastatic tumor
growth of mice injected with either nontarget shRNA or RalA- and RalB-targeting shRNA PC3 cells. Xenogen images shown were taken
at 6 weeks after injection in seven mice per group. Graphs indicate quantitation of total-body Xenogen signals at 3, 4, 5, and 6 weeks after
injection. *P < .05 compared with sh-nontarget control at 5 weeks.
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dilution. The Rac1 andCdc42 activation assays were carried out accord-
ing to the manufacturer’s protocol (Upstate, Charlottesville, VA).
In Vivo Xenograft Experiments
Five- to six-week-old male (for PC3 cell) or female (for UMUC3
cell) athymic nude mice (Ncr nu/nu) were obtained from the National
Cancer Institute (Frederick,MD). Animals weremaintained according
to the University of Virginia ICUC guidelines. For subcutaneous or
orthotopic tumorigenesis assays, 106 PC3 cells in 50 μl of serum-free
medium was mixed 1:1 with Matrigel (Becton Dickinson) immedi-
ately before injection. UMUC3 cells were suspended in serum-free
medium and injected at a concentration of 106 in 0.1 ml. PC3 and
UMUC3 cells were injected bilaterally into the subcutaneous flanks,
and tumors were evaluated as described [14]. To evaluate the ability of
UMUC3 for lung colonization, 4-week-old female mice were injected
through the tail vein with 5 × 106 cells suspended in 0.1 ml of serum-
free medium and evaluated by Xenogen bioluminescent imaging
(Caliper Life Sciences, Hopkinton,MA) as described [15], and a mod-
ification of a quantitative and sensitive DNA PCRmetastasis assay was
described previously by our laboratory [16]. We modified the assay
by use of human chromosome 12p primers and TaqMan probes. The
forward primer used for human 12p was 5′-TTCACTTTGGCA-
AATGTTTATCC-3′ and the reverse primer was 5′-GTGTG-
GGAAGGGATTAAACC-3′. The TaqMan probe was 5′-(Hex)
CCACGCAACCAGGCAA (BHQ1)-3′. To evaluate the ability of
PC3 cells for metastasis, 2 × 105 cells in serum-free medium were in-
oculated in the left ventricle, and bioluminescent in vivo imaging was
used to monitor metastasis weekly. At necropsy, gross tumor areas were
Figure 2. The effect of RalBP1 depletion on PC3 growth and metastasis. (A) Western blots demonstrating decreased RalBP1 protein
levels in PC3 cells after infection of lentiviral-based RalBP1-targeting shRNA constructs, shRalBP1-1 and shRalBP1-3. (B) i) In vitro
growth assessment of cells in panel A. Cell numbers were quantitated with Alamar blue at each time point. ii) In vivo subcutaneous
tumor growth of cells in panel A. Cells in serum-free RPMI medium were mixed with Matrigel and were subcutaneously injected into the
mouse flank region in five mice per group with two sites per mouse. Tumor volume was measured every week with a caliper. Error bars
represent SD. *P < .05 compared with sh-nontarget control at 5 weeks. (C) Xenogen evaluation of metastatic tumor growth of five mice
injected with either nontarget shRNA or two different RalBP1-targeting shRNA PC3 cells. Xenogen images shown were taken at 9 weeks
after injection. Graphs show quantitation of Xenogen signal at 3, 5, 7, and 9 weeks after injection. *P < .05 compared with sh-nontarget
control at 9 weeks. (D) Images of representative mouse mandibles dissected from mouse on necropsy. Arrows indicate where tumors
are located. (E) High-resolution CT images of mouse mandibles. Dissected mouse mandibles were imaged under a high-resolution CT
scanner to demonstrate bone destruction by PC3 tumors. Arrows indicate where tumors are located. (F) Xenogen evaluation of ortho-
topic tumor growth of six mice injected with either nontarget shRNA or RalBP1-targeting shRNA PC3 cells in mouse prostate. **P < .01
compared with sh-nontarget control at 6 weeks. Xenogen images shown were taken at 6 weeks after injection. (G) Mouse prostate
tumor size measured by a caliper at the time of necropsy at 6 weeks. **P < .01 compared with sh-nontarget control at 6 weeks from
mice described in panel F.
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dissected en bloc and imaged with high-resolution computed tomogra-
phy (CT) to examine the bone structure.
CT Imaging of Mice Mandibles
CT imaging of dissected tissues was performed on an open-barrel
type gantry consisting of two 38-in steel wheels connected by alumi-
num profile pieces. The CT subsystem built for small animal imaging
consists of a SourceBlock SB-80-1k x-ray source (Source Ray, Bohemia,
NY) and aHamamatsu C7940DP-03CMOS flat panel image sensor. It
was operated in 2 × 2 binningmode, resulting in a 1120 × 1172 detector
element matrix with a 100-μm pitch. Image acquisition and gantry
rotation are controlled by a custom-written LabView program. A CT
scan consisted of 400 projections, evenly spaced at 0.5-degree incre-
ments over 200 degrees. This arrangement results in a total acquisition
time of approximately 5minutes. These images were preprocessed using
a custom-written IDL program and reconstructed with a Feldkamp
back-projection algorithm (COBRA; Exxim, Inc, Pleasanton, CA).
Statistical Analysis
Data shown are representative of two or more experiments carried
out independently. Treatment group comparisons were evaluated us-
ing Student’s t test. Error bars are SD of the means. Values of P < .05
were taken as a significant difference between means.
Results
Depletion of RalA Affects Prostate Cancer Cell Migration and
In Vivo Growth and Metastasis
Previous studies indicated RalA but not RalB was essential for pros-
tate cancer migration andmetastasis to bone [5]. To begin determining
which RalA effector was likely involved in this process, we examined
the role of RalA as well as their known effectors RalBP1, Sec5, and
PLD1 in cell migration. Because Sec5 and Exo84 were both compo-
nents within exocyst complex, here we only evaluated Sec5. Transient
transfection of siRNA duplex specifically targeting RalA, RalBP1,
Sec5, and PLD1 decreased their mRNA expression level approxi-
mately 60% to 80% (Figure 1A) as evaluated by real-time RT-PCR,
which was chosen in lieu of Western analysis in view of its superior
quantitative reporting ability and ability to carry out comparison
across several targets obviating confounders such as antibody affinity.
All knockdowns were associated with a decrease in migration
(Figure 1B), whereas no effect on cell number was observed for any
siRNAs during the time course of the migration assay. Interestingly,
depletion of RalA or RalBP1 inhibited cell migration ∼60%, whereas
only ∼20% inhibition of cell migration was observed with Sec5 and
PLD1 reduction despite similar decreased RNA levels. Because
RalBP1 knockdown inhibited cell migration to a similar extent as RalA
Figure 2. (continued).
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depletion, we concluded that this effector may be an important con-
tributor to RalA-mediated in vivo metastasis.
The similar effect of RalA and RalBP1 knockdown on cell migration
prompted us to examine the consequences of such changes on PC3
tumor growth and metastasis. To do this, we created PC3 cells with
stable knockdown of RalA and RalB (Figure 1C ). Whereas depletion
of either Ral protein alone had no effect on in vitro cell growth consis-
tent with previous data [7], depletion of both RalA and RalB knock-
down showed inhibition on subcutaneous tumor growth (Figure 1D).
In contrast, RalA but not RalB significantly decreased PC3 cell bone
metastasis consistent with previous reports [5] (Figure 1E ).
Reduction of RalBP1 Phenocopies the Effects of RalA Depletion
on Prostate Tumor Growth and Metastasis
We also evaluated the effect of RalBP1 depletion on in vivo tumor
growth and metastasis. The protein level of RalBP1 was decreased by
∼90% after the infection of two lentiviral-based shRNA constructs tar-
geting RalBP1, sh-RalBP1-1, and sh-RalBP1-3 in PC3 cells (Figure 2A).
Decreased expression of RalBP1 had no effect on in vitro cell growth
(Figure 2Bi). In contrast to in vitro growth in monolayer cultures, de-
pletion of RalBP1 significantly inhibited in vitro tumor growth after
subcutaneous inoculation (Figure 2Bii). To assess the requirement
for RalBP1 expression for PC3 metastasis, we inoculated cells infected
with control and targeting shRNA constructs into the left ventricle of
mice. All mice injected with nontarget shRNA cells developed metas-
tasis 9 weeks after injection with most Xenogen signal concentrated in
limbs, axial skeleton, and mandibles (Figure 2C ). On necropsy, visible
tumors were seen onmouse mandibles (Figure 2D), and high-resolution
CTon dissected mandibles further confirmed the osteolytic destruction
typically produced by PC3 metastases (Figure 2E ). In contrast, none
of the mice injected with RalBP1-1 shRNA-infected cells developed
metastatic tumor in the 9-week period, and only one mouse showed
metastasis after injection with sh-RalBP1–3 infected cells (Figure 2C ).
To determine the requirement for RalBP1 expression for orthotopic
prostate cancer cell tumor growth and spontaneous metastasis, we
inoculated PC3 cells into mouse prostate. Depletion of RalBP1 by
lentiviral-based shRNA construct, sh-RalBP1-1, reduced orthotopic
tumor growth as measured by Xenogen bioluminescent signal
(Figure 2F ). This imaging monitored the inhibition of orthotopic
tumor growth as confirmed by actual measurement of the tumor at
necropsy (Figure 2G ). Mice injected with nontarget shRNA cells
developed liver (33%), kidney (67%), and adrenal gland (50%) me-
tastasis at the time of necropsy (Table 1). In contrast, none of the mice
inoculated with RalBP1-1–targeting shRNA cells developedmetastasis
in these organs, indicating that RalBP1 was necessary for PC3 cell
spontaneous metastasis from orthotopic tumors.
The necessary role of RalBP1 in local tumor growth and metastasis
led us to determine whether RalBP1 overexpression was sufficient to
further drive tumor growth and metastasis of PC3 cells. Stable RalBP1
Table 1. Metastasis Observed in Mice Orthotopically Injected with RalBP1 shRNA– and Control
shRNA–Engineered PC3 Cells.
Cell Line (No. Mice) No. Mice with Tumors at Site, n (%)
Kidney Liver Adrenal
sh-no target (6) 4 (67) 2 (33) 3 (50)
sh-RalBP1-1 (5) 0 (0) 0 (0) 0 (0)
Figure 3. Effect of RalBP1 overexpression on PC3 growth in vitro and metastasis in vivo. (A) Western blots showing Flag-tagged RalBP1
protein level in PC3 cells after stable transfection of RalBP1 transgene used in panels B to D. (B) In vitro cell number as a function of time
quantitated with Alamar blue. (C) In vivo subcutaneous tumor growth assessed by weekly tumor volume measurement in five mice
per group with two sites per mouse. (D) In vivo metastatic tumor growth assessment using Xenogen after intracardiac inoculation
as described in Materials and Methods in seven mice per group.
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overexpression in PC3 cells (Figure 3A) had no effect on in vitro cell
growth (Figure 3B) or in vivo subcutaneous tumor growth (Figure 3C )
and metastasis (Figure 3D), suggesting that overexpression of RalBP1
alone was not sufficient to further promote these characteristics in
prostate cancer PC3 cells.
RalBP1 Is Not the Major Mediator of RalA in Prostate Cancer
Cell In Vivo Metastasis
Because depletion of RalBP1 had a similar effect on in vivo tumor
growth and metastasis of PC3 as RalA knockdown and the former
is an effector of the latter, we sought to determine the importance of
RalA to RalBP1 binding in regulating PC3 metastasis. To do this, we
took advantage of the D49Nmutant of RalA that lost most of its bind-
ing to RalBP1 (Figure 4A), and the wild-type counterpart both made
shRNA-resistant as described inMaterials andMethods. These vectors
were then transfected into PC3 cells stably expressing either non-
target shRNA or RalA shRNA the latter with stably reduced RalA
(Figure 4B). Western blot for total cellular RalA showed similar ex-
pression levels between shRNA-resistant wild-type and D49Nmutant
RalA in both nontarget and RalA shRNA-transfected cells (Figure 4B).
Overexpression of wild-type or D49Nmutant RalA itself had no effect
on PC3 in vivo metastasis after intracardic inoculation of nontarget
transfected cells (Figure 4C ). Depletion of RalA significantly decreased
metastasis (Figure 4C ) as we saw before (Figure 1E ). Both wild-type
and D49N mutant RalA were able to rescue the effect of RalA de-
pletion on PC3 metastasis to a similar degree, suggesting that RalBP1
was not the primary downstream effector of RalA in maintaining
metastatic competence of PC3. Supporting the notion that RalA and
RalBP1 depletion may act on a different set of regulators of metastasis,
such depletions led to different effects on Rac1 and Cdc42 activity.
Whereas RalBP1 knockdown had no effect on Cdc42 levels or activity
but increased Rac1 activity, depletion of RalA decreased both total
and active Cdc42 levels and did not have a significant effect on Rac1
activity (Figure 4D).
Figure 4. Effect of RalA to RalBP1 binding on the function of RalA in PC3metastasis. (A) Immunoprecipitation (Flag pull-down, blot analysis
with RalBP1) in transfected PC3 cells demonstrating decreased association of D49Nmutant RalA to RalBP1 comparedwithwild-type RalA.
(B) RalA protein expression levels in either control shRNA or RalA-targeting shRNA PC3 cells stably transfected with wild-type RalA and
D49N mutant RalA. Wild type and D49N mutant RalA were shRNA resistant by virtue of a silent mutation as described in Materials and
Methods. *Flag tagged RalA, **endogenous RalA. (C) Xenogen evaluation of metastatic tumor growth of five mice per group injected
intracardiac with either nontarget shRNA or RalA-targeting shRNA PC3 cells in the context of stable expression of either wild-type RalA
or D49Nmutant RalA. Graphs show quantitation of Xenogen signal at 6, 7, and 8weeks after injection. (D) Rac1 and Cdc42 activation assay
in RalA, RalB, or RalBP1 depletion PC3 cells. Total lysate (10 μg of protein) or PAK1 pull-downs (from 1mg of protein) wereWestern blotted
with either Rac1 or Cdc42 antibody. Results shown are typical of experiments carried out in triplicate.
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RalBP1 Depletion Inhibits Human Bladder Cancer
Lung Colonization
The observed effect of RalBP1 on prostate cancer cell tumor growth
and metastasis led us to ask if the expression of this protein is also nec-
essary for tumor growth and metastasis in other tumor types such as
bladder cancer, where RalA expression is associated with higher tumor
stage [7]. Bladder cancer is particularly relevant because RalBP1 is
highly expressed in this tumor type at both protein [6] and RNA levels
[17]. We stably depleted RalBP1 in the bladder cancer UMUC3
cell line with lentiviral-based shRNA construct targeting RalBP1
(Figure 5A). Depletion of RalBP1 in UMUC3 cells had no effect
on their in vitro growth (Figure 5B). After subcutaneous inoculation,
tumors from RalBP1 knockdown UMUC3 cells displayed slower
growth rate compared with that from nontarget shRNAUMUC3 cells,
but this difference did not reach statistical significance (Figure 5C ).
Because the major metastatic site of bladder cancer is lung, we used
the lung colonization assay following the tail vein inoculation of
UMUC3 cells to study the role of RalBP1 in bladder cancer metas-
tasis. Depletion of RalBP1 in UMUC3 cells decreased metastasis as
assessed by Xenogen bioluminescent signal 6 weeks on both chest
area and whole body area (Figure 5D). This finding was confirmed
at necropsy using PCR for human-specific DNA in mouse lungs
(Figure 5E ).
Discussion
Ral proteins were initially identified as Ras effectors of transformation.
However, more recent studies have demonstrated their essential role in
cancer migration and metastasis. In prostate cancer, RalA seems to be
necessary for these processes [5], and the expression of this protein is
associated with human tumor progression [18]. Here, we evaluated
common RalA effectors for their role in human prostate cancer cell
migration and identified RalBP1 as an important mediator of this pro-
cess. However, whereas siRNA-mediated knockdown of Sec5 and
PLD1 inhibited cell migration to a lesser extent compared with that
of RalBP1 depletion, we cannot exclude them from a role in Ral-
mediated cancer metastasis because cell migration is only one aspect
determining the metastatic potential of cancer cells.
Figure 5. Effect of RalBP1 depletion on bladder cancer growth in vivo and lung colonization. (A) Western blots demonstrating diminished
RalBP1 protein levels in UMUC3 cells after infection of lentiviral-based RalBP1-targeting shRNA constructs: shRalBP1-1 and shRalBP1-3.
(B) In vitro growth assessment of cells in panel A. Cells were plated in 96-well plates with duplicate plates for each time point. Cell numbers
were quantitatedwith Alamar blue at each time point. (C) In vivo subcutaneous tumor growth of cells in panel A. UMUC3 cells in serum-free
RPMImediumwere subcutaneously injected into the mouse flanks in five mice per group with two sites per mouse. Tumor volumes were
measuredweeklywith calipers. (D) Xenogen evaluation ofmetastatic tumor growth inmice (fivemice per group) tail vein injectedwith cells
as described in panel A. Graphs show quantitation of Xenogen signal of whole body and chest area after 6 weeks of tail vein inoculation.
*P < .05, **P < .01 compared with sh-nontarget control. (E) Images of representative mouse lungs (from mice described in panel D)
dissected from mouse after necropsy and fixed in Bouin solution to facilitate visualization of the tumor nodule on the surface of the lung.
Mouse lungs were dissected, genomic DNA was isolated, and human-specific real-time PCR quantitation of human tumor cells in mouse
lung was carried out as described in Materials and Methods. **P < .01 compared with sh-nontarget control.
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The similar inhibition of cell migration by RalA and RalBP1 deple-
tion prompted us to further characterize the function of RalBP1 in
RalA-dependent metastasis. Although RalBP1 depletion significantly
inhibited the in vivo growth and metastasis of PC3 prostate cancer
cells, further expression of this protein in PC3 had no effect on these
phenotypes. This finding corroborated that of Awasthi et al. [19] who
found that RalBP1 was essential for subcutaneous tumor growth of
B16 melanomas, H358 and H520 non–small cell lung cancer, and
SW480 colon carcinomas. Such findings were analogous to those with
RalA that was found to be necessary for PC3 metastasis but was not
sufficient to make them more aggressive [5]. This could occur if both
RalA and RalBP1 are in excess compared with a limiting effector.
RalBP1 depletion inhibited subcutaneous tumor growth of PC3 but
not UMUC3 cells. This may be due to the different effects of this
GTPase in different tumor types or may be a cell-specific effect. Sim-
ilarly, RalA knockdown inhibited subcutaneous growth and metastasis
of PC3, although a previous study showed that RalA depletion only
had an effect on metastasis [5]. This discrepancy could be due to the
different cell numbers injected. The possibility that the decrease inme-
tastasis could result from decreased tumor growth at the primary (ortho-
topic) site also exists, and to determine this, one would need to compare
tumors of the same size in the orthotopic location and use this to in-
terpret the metastatic load. Our tail vein injection does not address
this issue because this is a measure of metastatic colonization.
Perhaps most provocatively, although RalBP1 and RalA depletion
had a similar effect on tumor growth and metastasis in PC3, the result
with the D49N mutant RalA experiment pointed out that binding of
RalA to RalBP1 is not required for the RalA’s effect in PC3 cell metas-
tasis. We also noted that PC3 cells with chronically depleted RalA that
were transfectedwith wild-typeRalA did not recover their full metastatic
potential, although the total RalA levels were similar to cells before de-
pletion. This finding may have several explanations. The first is that the
RalA shRNA is still exerting an off-target effect on the PC3 cells that
is affecting their metastatic competence without affecting other
RalA-mediated in vitro phenotypes such as migration. Another possi-
bility is that chronic depletion of RalA has selected cells that are not as
susceptible to promotion of themetastatic phenotype by RalA overexpres-
sion. Finally, the FLAG tag may not produce a functionally equivalent
RalA protein at least for themetastatic phenotype we are evaluating here.
Nevertheless, the conclusion that RalBP1 is not required for the
RalA’s effect on PC3 cell metastasis is further supported by the differ-
ent effects of RalA and RalBP1 depletion on Rac1 and Cdc42 activity.
Depletion of RalBP1 increased activity of Rac1 consistent with a pre-
vious study showing that RalBP1 has a GTPase-activating (GAP) ac-
tivity toward Rac1 [20]. In contrast, RalA depletion had no effect on
Rac1 activity while significantly decreasing both total and active
Cdc42 levels, indicating that the effect of RalA knockdown on these
proteins may not be completely mediated through RalBP1. Suppres-
sion of TBK1 or RalB has recently been shown to lead to selective
lethality in KRAS-dependent cell lines [21], consistent with a previous
work linking RalB through Sec5 to TBK1 activation in the setting of
tumor cell survival [22]. Hence, paralog-specific effector use may be a
possibility that can also explain our findings.
In contrast to these findings, there is evidence that RalBP1 is in-
volved in transformation and tumorigenesis mediated by Aurora-A
phosphorylation of RalA at S194 [23]. In addition, both Ral and
RalBP1 play important roles in ligand-mediated receptor endocytosis,
and the interaction between RalA and RalBP1 and their subsequent
translocation to membrane was essential for this process [24]. Whereas
the dependence of these processes on the Ral-RalBP1 interaction could
potentially affect in vivo cancer cell growth andmetastasis, it may not be
operative in all cases or systems (PC3) or tumor histologies (prostate).
In summary, our studies are the first to demonstrate an essential role
of RalBP1 in spontaneous and experimental metastasis. This lays the
foundation of RalBP1 as a promising target for therapy for this deadly
form of cancer.
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